Top Markets
#1 Islamic Coin Islamic Coin +154.27%
#2 PulseChain PulseChain +52.83%
#3 BOOK OF MEME BOOK OF MEME +44.89%
#4 DogBull DogBull +34.92%
#5 Nockchain Nockchain +18.68%
#6 ORDI ORDI +17.36%
#7 Ergo Ergo +17.32%
#8 rsERG rsERG +16.99%
#9 Bio Protocol Bio Protocol +16.75%
#10 PondCoin PondCoin +16.22%
Coin of the day
Islamic Coin Islamic Coin
設定
言語
日本
通貨
USD
テーマ
Grace Therapeutics, Inc. Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

GRCE
株式のランク #27036
Grace Therapeutics, Inc. specializes in the creation and commercialization of... Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
株価
$2.18
最終同期: 2026-08-19
時価総額
$35.55M
変化（1日）
2.57%
変化（1年）
-33.19%
国
US
取引 Grace Therapeutics, Inc. (GRCE)

カテゴリー

Healthcare
Grace Therapeutics, Inc.（GRCE）の収益
Aug 2026 時点の収益 TTM: 0
Grace Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Grace Therapeutics, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH